Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3

Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer who were treatment naïve or had received up to one line of prior endocrine therapy in the advanced setting. Patients...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical oncology Jg. 36; H. 24; S. 2465
Hauptverfasser: Slamon, Dennis J, Neven, Patrick, Chia, Stephen, Fasching, Peter A, De Laurentiis, Michelino, Im, Seock-Ah, Petrakova, Katarina, Bianchi, Giulia Val, Esteva, Francisco J, Martín, Miguel, Nusch, Arnd, Sonke, Gabe S, De la Cruz-Merino, Luis, Beck, J Thaddeus, Pivot, Xavier, Vidam, Gena, Wang, Yingbo, Rodriguez Lorenc, Karen, Miller, Michelle, Taran, Tetiana, Jerusalem, Guy
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 20.08.2018
ISSN:1527-7755, 1527-7755
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer who were treatment naïve or had received up to one line of prior endocrine therapy in the advanced setting. Patients and Methods Patients were randomly assigned at a two-to-one ratio to ribociclib plus fulvestrant or placebo plus fulvestrant. The primary end point was locally assessed progression-free survival. Secondary end points included overall survival, overall response rate, and safety. Results A total of 484 postmenopausal women were randomly assigned to ribociclib plus fulvestrant, and 242 were assigned to placebo plus fulvestrant. Median progression-free survival was significantly improved with ribociclib plus fulvestrant versus placebo plus fulvestrant: 20.5 months (95% CI, 18.5 to 23.5 months) versus 12.8 months (95% CI, 10.9 to 16.3 months), respectively (hazard ratio, 0.593; 95% CI, 0.480 to 0.732; P < .001). Consistent treatment effects were observed in patients who were treatment naïve in the advanced setting (hazard ratio, 0.577; 95% CI, 0.415 to 0.802), as well as in patients who had received up to one line of prior endocrine therapy for advanced disease (hazard ratio, 0.565; 95% CI, 0.428 to 0.744). Among patients with measurable disease, the overall response rate was 40.9% for the ribociclib plus fulvestrant arm and 28.7% for placebo plus fulvestrant. Grade 3 adverse events reported in ≥ 10% of patients in either arm (ribociclib plus fulvestrant v placebo plus fulvestrant) were neutropenia (46.6% v 0%) and leukopenia (13.5% v 0%); the only grade 4 event reported in ≥ 5% of patients was neutropenia (6.8% v 0%). Conclusion Ribociclib plus fulvestrant might represent a new first- or second-line treatment option in hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.
AbstractList Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer who were treatment naïve or had received up to one line of prior endocrine therapy in the advanced setting. Patients and Methods Patients were randomly assigned at a two-to-one ratio to ribociclib plus fulvestrant or placebo plus fulvestrant. The primary end point was locally assessed progression-free survival. Secondary end points included overall survival, overall response rate, and safety. Results A total of 484 postmenopausal women were randomly assigned to ribociclib plus fulvestrant, and 242 were assigned to placebo plus fulvestrant. Median progression-free survival was significantly improved with ribociclib plus fulvestrant versus placebo plus fulvestrant: 20.5 months (95% CI, 18.5 to 23.5 months) versus 12.8 months (95% CI, 10.9 to 16.3 months), respectively (hazard ratio, 0.593; 95% CI, 0.480 to 0.732; P < .001). Consistent treatment effects were observed in patients who were treatment naïve in the advanced setting (hazard ratio, 0.577; 95% CI, 0.415 to 0.802), as well as in patients who had received up to one line of prior endocrine therapy for advanced disease (hazard ratio, 0.565; 95% CI, 0.428 to 0.744). Among patients with measurable disease, the overall response rate was 40.9% for the ribociclib plus fulvestrant arm and 28.7% for placebo plus fulvestrant. Grade 3 adverse events reported in ≥ 10% of patients in either arm (ribociclib plus fulvestrant v placebo plus fulvestrant) were neutropenia (46.6% v 0%) and leukopenia (13.5% v 0%); the only grade 4 event reported in ≥ 5% of patients was neutropenia (6.8% v 0%). Conclusion Ribociclib plus fulvestrant might represent a new first- or second-line treatment option in hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer who were treatment naïve or had received up to one line of prior endocrine therapy in the advanced setting. Patients and Methods Patients were randomly assigned at a two-to-one ratio to ribociclib plus fulvestrant or placebo plus fulvestrant. The primary end point was locally assessed progression-free survival. Secondary end points included overall survival, overall response rate, and safety. Results A total of 484 postmenopausal women were randomly assigned to ribociclib plus fulvestrant, and 242 were assigned to placebo plus fulvestrant. Median progression-free survival was significantly improved with ribociclib plus fulvestrant versus placebo plus fulvestrant: 20.5 months (95% CI, 18.5 to 23.5 months) versus 12.8 months (95% CI, 10.9 to 16.3 months), respectively (hazard ratio, 0.593; 95% CI, 0.480 to 0.732; P < .001). Consistent treatment effects were observed in patients who were treatment naïve in the advanced setting (hazard ratio, 0.577; 95% CI, 0.415 to 0.802), as well as in patients who had received up to one line of prior endocrine therapy for advanced disease (hazard ratio, 0.565; 95% CI, 0.428 to 0.744). Among patients with measurable disease, the overall response rate was 40.9% for the ribociclib plus fulvestrant arm and 28.7% for placebo plus fulvestrant. Grade 3 adverse events reported in ≥ 10% of patients in either arm (ribociclib plus fulvestrant v placebo plus fulvestrant) were neutropenia (46.6% v 0%) and leukopenia (13.5% v 0%); the only grade 4 event reported in ≥ 5% of patients was neutropenia (6.8% v 0%). Conclusion Ribociclib plus fulvestrant might represent a new first- or second-line treatment option in hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.
Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer who were treatment naïve or had received up to one line of prior endocrine therapy in the advanced setting. Patients and Methods Patients were randomly assigned at a two-to-one ratio to ribociclib plus fulvestrant or placebo plus fulvestrant. The primary end point was locally assessed progression-free survival. Secondary end points included overall survival, overall response rate, and safety. Results A total of 484 postmenopausal women were randomly assigned to ribociclib plus fulvestrant, and 242 were assigned to placebo plus fulvestrant. Median progression-free survival was significantly improved with ribociclib plus fulvestrant versus placebo plus fulvestrant: 20.5 months (95% CI, 18.5 to 23.5 months) versus 12.8 months (95% CI, 10.9 to 16.3 months), respectively (hazard ratio, 0.593; 95% CI, 0.480 to 0.732; P < .001). Consistent treatment effects were observed in patients who were treatment naïve in the advanced setting (hazard ratio, 0.577; 95% CI, 0.415 to 0.802), as well as in patients who had received up to one line of prior endocrine therapy for advanced disease (hazard ratio, 0.565; 95% CI, 0.428 to 0.744). Among patients with measurable disease, the overall response rate was 40.9% for the ribociclib plus fulvestrant arm and 28.7% for placebo plus fulvestrant. Grade 3 adverse events reported in ≥ 10% of patients in either arm (ribociclib plus fulvestrant v placebo plus fulvestrant) were neutropenia (46.6% v 0%) and leukopenia (13.5% v 0%); the only grade 4 event reported in ≥ 5% of patients was neutropenia (6.8% v 0%). Conclusion Ribociclib plus fulvestrant might represent a new first- or second-line treatment option in hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.
Author Vidam, Gena
De Laurentiis, Michelino
Jerusalem, Guy
De la Cruz-Merino, Luis
Fasching, Peter A
Esteva, Francisco J
Martín, Miguel
Slamon, Dennis J
Miller, Michelle
Chia, Stephen
Neven, Patrick
Sonke, Gabe S
Petrakova, Katarina
Rodriguez Lorenc, Karen
Beck, J Thaddeus
Taran, Tetiana
Pivot, Xavier
Nusch, Arnd
Im, Seock-Ah
Bianchi, Giulia Val
Wang, Yingbo
Author_xml – sequence: 1
  givenname: Dennis J
  surname: Slamon
  fullname: Slamon, Dennis J
  organization: Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland
– sequence: 2
  givenname: Patrick
  surname: Neven
  fullname: Neven, Patrick
  organization: Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland
– sequence: 3
  givenname: Stephen
  surname: Chia
  fullname: Chia, Stephen
  organization: Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland
– sequence: 4
  givenname: Peter A
  surname: Fasching
  fullname: Fasching, Peter A
  organization: Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland
– sequence: 5
  givenname: Michelino
  surname: De Laurentiis
  fullname: De Laurentiis, Michelino
  organization: Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland
– sequence: 6
  givenname: Seock-Ah
  surname: Im
  fullname: Im, Seock-Ah
  organization: Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland
– sequence: 7
  givenname: Katarina
  surname: Petrakova
  fullname: Petrakova, Katarina
  organization: Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland
– sequence: 8
  givenname: Giulia Val
  surname: Bianchi
  fullname: Bianchi, Giulia Val
  organization: Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland
– sequence: 9
  givenname: Francisco J
  surname: Esteva
  fullname: Esteva, Francisco J
  organization: Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland
– sequence: 10
  givenname: Miguel
  surname: Martín
  fullname: Martín, Miguel
  organization: Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland
– sequence: 11
  givenname: Arnd
  surname: Nusch
  fullname: Nusch, Arnd
  organization: Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland
– sequence: 12
  givenname: Gabe S
  surname: Sonke
  fullname: Sonke, Gabe S
  organization: Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland
– sequence: 13
  givenname: Luis
  surname: De la Cruz-Merino
  fullname: De la Cruz-Merino, Luis
  organization: Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland
– sequence: 14
  givenname: J Thaddeus
  surname: Beck
  fullname: Beck, J Thaddeus
  organization: Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland
– sequence: 15
  givenname: Xavier
  surname: Pivot
  fullname: Pivot, Xavier
  organization: Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland
– sequence: 16
  givenname: Gena
  surname: Vidam
  fullname: Vidam, Gena
  organization: Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland
– sequence: 17
  givenname: Yingbo
  surname: Wang
  fullname: Wang, Yingbo
  organization: Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland
– sequence: 18
  givenname: Karen
  surname: Rodriguez Lorenc
  fullname: Rodriguez Lorenc, Karen
  organization: Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland
– sequence: 19
  givenname: Michelle
  surname: Miller
  fullname: Miller, Michelle
  organization: Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland
– sequence: 20
  givenname: Tetiana
  surname: Taran
  fullname: Taran, Tetiana
  organization: Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland
– sequence: 21
  givenname: Guy
  surname: Jerusalem
  fullname: Jerusalem, Guy
  organization: Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29860922$$D View this record in MEDLINE/PubMed
BookMark eNpNkMlOwzAQhi0EYr9zQnPkQIrtxE3MrVRdgkpbFThX48QFoyQudlIEz8RDkopFnGZG8_2z_Edkt7KVJuSM0Q7jlF7d9mcdTlnSiZOOlFTukEMmeBzEsRC7__IDcuT9C6UsSkKxTw64TLpUcn5IPufP6DWkaQoLrHJbmg-dw33d5O9gV7AwymYmK4yCtgvDpthoXzusajAVjK0r24NgoTO9rq0L5tab2mz0JYybEisYrE2uXYkFjJx9q59hiFnL_QmAB1P9hFsJ9PINVlm7_MZp9DX0t5W7hrvZtDcZDO57QXhC9lZYeH36E4_J43Dw0B8Hk9ko7fcmQRZRWQdKR0KyOMxyRMa4ah3ibEWZkLGMIxSx7LJVopRWUdhSjHUFMopCCpkrmnT5Mbn4nrt29rVpH16Wxme6KLDStvFLTiMpI8EkbdHzH7RRpc6Xa2dKdO_LX4f5FxJLftw
CitedBy_id crossref_primary_10_2147_DDDT_S314723
crossref_primary_10_1038_s41598_021_89126_2
crossref_primary_10_1177_1060028018793656
crossref_primary_10_3390_jpm11080808
crossref_primary_10_1186_s12885_020_07546_1
crossref_primary_10_3390_cells9071643
crossref_primary_10_1007_s10549_019_05318_5
crossref_primary_10_1016_j_ctarc_2024_100818
crossref_primary_10_1007_s11864_019_0657_y
crossref_primary_10_1080_14737167_2022_2108409
crossref_primary_10_1097_CM9_0000000000000745
crossref_primary_10_3389_fonc_2019_00510
crossref_primary_10_1007_s00404_019_05304_8
crossref_primary_10_1002_bcp_70265
crossref_primary_10_2147_BCTT_S196240
crossref_primary_10_1016_j_esmoop_2025_105121
crossref_primary_10_1016_j_hemonc_2020_03_001
crossref_primary_10_1007_s12609_022_00461_3
crossref_primary_10_6061_clinics_2021_e3146
crossref_primary_10_1007_s40259_019_00382_1
crossref_primary_10_1200_GO_25_00139
crossref_primary_10_1007_s10549_019_05176_1
crossref_primary_10_3390_medsci8010018
crossref_primary_10_1016_j_clbc_2021_01_017
crossref_primary_10_1080_07357907_2021_1910705
crossref_primary_10_1177_87551225231205153
crossref_primary_10_1007_s00508_025_02582_y
crossref_primary_10_1159_000501304
crossref_primary_10_1016_j_breast_2025_104568
crossref_primary_10_3389_fonc_2021_643155
crossref_primary_10_1016_j_critrevonc_2020_103191
crossref_primary_10_1016_j_breast_2025_104448
crossref_primary_10_1080_14737140_2021_1840360
crossref_primary_10_1158_1078_0432_CCR_21_1565
crossref_primary_10_1007_s10549_023_06993_1
crossref_primary_10_1016_j_ejca_2023_113480
crossref_primary_10_1177_17588359231152843
crossref_primary_10_3390_cancers15194835
crossref_primary_10_1200_GO_20_00566
crossref_primary_10_1016_j_clbc_2019_04_015
crossref_primary_10_3390_cancers12082296
crossref_primary_10_1016_S0140_6736_20_30165_3
crossref_primary_10_1093_ehjci_jeac106
crossref_primary_10_1158_1078_0432_CCR_23_0956
crossref_primary_10_1016_j_cpcardiol_2018_10_003
crossref_primary_10_1007_s40262_023_01338_z
crossref_primary_10_1016_j_thromres_2021_11_009
crossref_primary_10_1188_19_CJON_434_438
crossref_primary_10_1016_j_breast_2025_104412
crossref_primary_10_1007_s12672_025_02571_7
crossref_primary_10_1038_s41417_022_00473_2
crossref_primary_10_1080_14656566_2019_1672659
crossref_primary_10_3390_cancers13020332
crossref_primary_10_3390_cancers14205132
crossref_primary_10_1016_j_ctrv_2018_07_013
crossref_primary_10_1080_14737140_2021_1944109
crossref_primary_10_1016_j_jelechem_2020_114722
crossref_primary_10_1016_j_esmoop_2025_104290
crossref_primary_10_1016_j_ctrv_2025_102956
crossref_primary_10_1007_s00280_021_04254_w
crossref_primary_10_1007_s10549_019_05198_9
crossref_primary_10_1038_s41523_024_00708_5
crossref_primary_10_1016_j_bulcan_2020_07_005
crossref_primary_10_1016_S1875_5364_25_60846_6
crossref_primary_10_1177_10781552251317962
crossref_primary_10_1007_s11912_023_01393_6
crossref_primary_10_1158_1078_0432_CCR_20_0844
crossref_primary_10_1053_j_seminoncol_2021_06_003
crossref_primary_10_1186_s12885_024_12782_w
crossref_primary_10_3390_cancers17121941
crossref_primary_10_1111_jgs_15943
crossref_primary_10_4081_oncol_2019_416
crossref_primary_10_1158_1078_0432_CCR_22_1281
crossref_primary_10_1016_S1470_2045_19_30420_6
crossref_primary_10_1007_s40265_024_02144_y
crossref_primary_10_1007_s40273_021_01027_4
crossref_primary_10_3390_cancers13112640
crossref_primary_10_1007_s00761_019_0574_5
crossref_primary_10_1016_j_critrevonc_2020_103029
crossref_primary_10_3389_fphar_2020_580251
crossref_primary_10_1111_ajco_13461
crossref_primary_10_3389_fphar_2019_01235
crossref_primary_10_1016_j_bulcan_2020_01_010
crossref_primary_10_1007_s10549_020_05528_2
crossref_primary_10_2217_fon_2021_0842
crossref_primary_10_1016_j_ejca_2022_03_006
crossref_primary_10_1007_s11523_018_0587_9
crossref_primary_10_1007_s12254_023_00878_1
crossref_primary_10_1093_jnci_djaa087
crossref_primary_10_1007_s15015_019_0010_0
crossref_primary_10_3390_cancers14102470
crossref_primary_10_1159_000504618
crossref_primary_10_1038_s41467_024_46495_2
crossref_primary_10_2147_OTT_S298720
crossref_primary_10_1177_1060028018817904
crossref_primary_10_1002_jms_4984
crossref_primary_10_1016_j_coemr_2020_10_008
crossref_primary_10_3390_biomedicines11123343
crossref_primary_10_1038_s41523_019_0121_y
crossref_primary_10_1007_s10549_019_05133_y
crossref_primary_10_1016_j_annonc_2023_11_003
crossref_primary_10_3389_fonc_2021_759150
crossref_primary_10_3390_jcm13071873
crossref_primary_10_2147_PPA_S401480
crossref_primary_10_1016_j_ejca_2024_113555
crossref_primary_10_1186_s13058_020_01271_0
crossref_primary_10_3390_medicina61071279
crossref_primary_10_3390_ph17070927
crossref_primary_10_1007_s00761_024_01510_5
crossref_primary_10_3390_jpm14090895
crossref_primary_10_1007_s10549_023_07226_1
crossref_primary_10_1016_j_humpath_2025_105905
crossref_primary_10_3389_fonc_2019_00666
crossref_primary_10_1111_1759_7714_14715
crossref_primary_10_1111_tbj_13940
crossref_primary_10_1200_GO_23_00484
crossref_primary_10_1007_s40256_024_00709_6
crossref_primary_10_4103_ijc_IJC_30_21
crossref_primary_10_1038_s41416_020_01174_z
crossref_primary_10_1080_03007995_2022_2073122
crossref_primary_10_3390_cancers13081928
crossref_primary_10_3390_ijms25020732
crossref_primary_10_2217_cer_2020_0230
crossref_primary_10_1038_s41586_019_1056_z
crossref_primary_10_1007_s11096_020_01193_z
crossref_primary_10_1016_j_critrevonc_2022_103848
crossref_primary_10_1186_s13058_021_01411_0
crossref_primary_10_1016_j_jbc_2023_105021
crossref_primary_10_1158_1078_0432_CCR_22_2206
crossref_primary_10_1097_CM9_0000000000000923
crossref_primary_10_1097_GCO_0000000000000511
crossref_primary_10_1186_s40364_021_00271_2
crossref_primary_10_1007_s00761_021_01060_0
crossref_primary_10_1097_GCO_0000000000000510
crossref_primary_10_1002_cnr2_1575
crossref_primary_10_7759_cureus_23901
crossref_primary_10_3389_fphar_2024_1371346
crossref_primary_10_1007_s12094_021_02766_8
crossref_primary_10_1016_j_critrevonc_2024_104296
crossref_primary_10_1007_s00604_021_04735_y
crossref_primary_10_1016_j_canlet_2024_217120
crossref_primary_10_3389_fendo_2022_1075830
crossref_primary_10_1016_j_breast_2023_08_007
crossref_primary_10_1007_s00129_021_04792_7
crossref_primary_10_1177_10781552221119797
crossref_primary_10_3389_fphar_2020_00891
crossref_primary_10_3390_ijms21061960
crossref_primary_10_1002_ijc_33959
crossref_primary_10_1038_s41586_024_08035_2
crossref_primary_10_1007_s11684_020_0795_4
crossref_primary_10_1210_en_2018_01095
crossref_primary_10_1016_S1470_2045_19_30804_6
crossref_primary_10_1158_1078_0432_CCR_20_0645
crossref_primary_10_3390_genes13060960
crossref_primary_10_1186_s12885_024_12269_8
crossref_primary_10_1177_17588359221139678
crossref_primary_10_3390_medicina61010154
crossref_primary_10_3389_fonc_2024_1413674
crossref_primary_10_2217_cer_2021_0221
crossref_primary_10_1038_s41698_025_01041_1
crossref_primary_10_1080_14656566_2020_1738385
crossref_primary_10_1186_s12964_023_01142_z
crossref_primary_10_3389_fphar_2024_1378090
crossref_primary_10_1080_14740338_2025_2465852
crossref_primary_10_3390_life12030378
crossref_primary_10_1001_jamanetworkopen_2020_20312
crossref_primary_10_1186_s12915_025_02295_8
crossref_primary_10_1056_NEJMoa1811714
crossref_primary_10_1016_j_esmorw_2024_100064
crossref_primary_10_1038_s41698_023_00438_0
crossref_primary_10_1016_j_diamond_2025_112001
crossref_primary_10_1055_a_1464_1221
crossref_primary_10_1002_mco2_181
crossref_primary_10_1097_CAD_0000000000000904
crossref_primary_10_1177_17588359221100865
crossref_primary_10_1007_s40944_019_0363_5
crossref_primary_10_1007_s00520_022_06823_y
crossref_primary_10_1007_s12265_019_09924_y
crossref_primary_10_1186_s13045_022_01362_9
crossref_primary_10_1177_10781552241279019
crossref_primary_10_1177_17588359241302018
crossref_primary_10_1016_j_ygyno_2025_08_024
crossref_primary_10_1080_03007995_2024_2402074
crossref_primary_10_1080_14737140_2023_2171993
crossref_primary_10_1002_mco2_97
crossref_primary_10_3389_fonc_2022_1009352
crossref_primary_10_3389_fonc_2022_931371
crossref_primary_10_2217_cer_2020_0272
crossref_primary_10_1186_s12916_022_02260_0
crossref_primary_10_1007_s12094_019_02269_7
crossref_primary_10_1016_j_clbc_2021_07_013
crossref_primary_10_1186_s13058_024_01902_w
crossref_primary_10_1002_onco_13866
crossref_primary_10_1093_jncics_pkad045
crossref_primary_10_1016_j_annonc_2025_03_023
crossref_primary_10_1007_s00761_020_00766_x
crossref_primary_10_1016_j_critrevonc_2023_104148
crossref_primary_10_3390_ijms21186479
crossref_primary_10_1007_s00129_019_4415_9
crossref_primary_10_1200_JCO_24_01865
crossref_primary_10_1158_1078_0432_CCR_19_0471
crossref_primary_10_1038_s41571_018_0165_1
crossref_primary_10_1177_10781552231180463
crossref_primary_10_1016_j_breast_2025_103875
crossref_primary_10_1007_s11864_019_0651_4
crossref_primary_10_1016_j_clbc_2019_05_019
crossref_primary_10_1016_S1470_2045_19_30026_9
crossref_primary_10_3390_ijms26062643
crossref_primary_10_1016_j_heliyon_2024_e31583
crossref_primary_10_1016_j_clbc_2019_05_010
crossref_primary_10_1016_j_ejca_2025_115225
crossref_primary_10_1159_000508675
crossref_primary_10_3390_ijms242216198
crossref_primary_10_1158_1078_0432_CCR_21_3131
crossref_primary_10_1186_s12967_018_1734_x
crossref_primary_10_3390_cancers15061908
crossref_primary_10_1038_s41392_024_02080_z
crossref_primary_10_3389_fonc_2023_1128443
crossref_primary_10_1016_j_ejim_2024_08_005
crossref_primary_10_1007_s10549_021_06215_6
crossref_primary_10_1080_07853890_2025_2557509
crossref_primary_10_1093_jnci_djaa071
crossref_primary_10_1007_s10549_024_07415_6
crossref_primary_10_1177_0300891620976981
crossref_primary_10_36290_xon_2019_005
crossref_primary_10_1080_0284186X_2023_2194030
crossref_primary_10_1177_17588359241273026
crossref_primary_10_3390_ijms21176400
crossref_primary_10_1007_s00520_022_07320_y
crossref_primary_10_1016_j_ctrv_2020_102136
crossref_primary_10_3390_ijms241411791
crossref_primary_10_2217_fon_2020_0604
crossref_primary_10_3390_cancers12092480
crossref_primary_10_1093_jjco_hyz151
crossref_primary_10_1002_ctm2_1544
crossref_primary_10_1080_17568919_2025_2467615
crossref_primary_10_3389_fphar_2024_1269922
crossref_primary_10_1055_a_1912_7362
crossref_primary_10_1001_jamanetworkopen_2022_4361
crossref_primary_10_1016_S1470_2045_23_00172_9
crossref_primary_10_21518_2079_701X_2021_4S_103_107
crossref_primary_10_1097_MD_0000000000035487
crossref_primary_10_3390_cancers13225643
crossref_primary_10_1002_med_21856
crossref_primary_10_3390_cancers16091749
crossref_primary_10_3389_fonc_2022_956464
crossref_primary_10_2147_CMAR_S325043
crossref_primary_10_1055_a_1111_8775
crossref_primary_10_1200_EDBK_279465
crossref_primary_10_1007_s11427_021_2140_8
crossref_primary_10_1016_j_currproblcancer_2020_100606
crossref_primary_10_1158_1078_0432_CCR_21_3032
crossref_primary_10_3389_fonc_2025_1529980
crossref_primary_10_3390_cancers15184653
crossref_primary_10_1080_0284186X_2020_1738547
crossref_primary_10_1002_cam4_4767
crossref_primary_10_2147_TCRM_S391769
crossref_primary_10_1002_onco_13531
crossref_primary_10_1080_13102818_2023_2268753
crossref_primary_10_1038_s41523_023_00520_7
crossref_primary_10_2340_1651_226X_2025_43226
crossref_primary_10_1158_2159_8290_CD_19_0050
crossref_primary_10_1007_s11033_020_06100_3
crossref_primary_10_1186_s12885_025_14308_4
crossref_primary_10_1038_s41416_021_01564_x
crossref_primary_10_1016_j_clbc_2019_06_017
crossref_primary_10_1080_14737140_2022_2052277
crossref_primary_10_1007_s12254_021_00718_0
crossref_primary_10_1016_S1470_2045_20_30642_2
crossref_primary_10_1038_s41420_025_02336_9
crossref_primary_10_7759_cureus_84418
crossref_primary_10_1016_j_breast_2020_09_008
crossref_primary_10_1080_14740338_2024_2307375
crossref_primary_10_4103_ejcrp_eJCRP_D_23_00008
crossref_primary_10_1016_j_breast_2021_02_015
crossref_primary_10_1007_s12609_020_00392_x
crossref_primary_10_1002_onco_13660
crossref_primary_10_1038_s41523_025_00726_x
crossref_primary_10_1007_s00520_023_08160_0
crossref_primary_10_1158_1078_0432_CCR_24_1724
crossref_primary_10_1056_NEJMoa2305488
crossref_primary_10_1111_cas_14554
crossref_primary_10_1016_j_ctarc_2023_100683
crossref_primary_10_1016_j_annonc_2024_09_010
crossref_primary_10_2478_fco_2019_0007
crossref_primary_10_1007_s10549_021_06173_z
crossref_primary_10_1055_s_0041_1736239
crossref_primary_10_1002_jcph_1825
crossref_primary_10_1002_jcph_1856
crossref_primary_10_2147_OTT_S400563
crossref_primary_10_3390_cancers11111802
crossref_primary_10_1016_j_breast_2023_05_002
crossref_primary_10_1056_NEJMoa1911149
crossref_primary_10_1177_1758835919827714
crossref_primary_10_1016_j_bbamcr_2022_119346
crossref_primary_10_1080_14656566_2023_2201373
crossref_primary_10_1038_s41388_025_03378_0
crossref_primary_10_1055_a_1724_9569
crossref_primary_10_1016_j_clbc_2021_08_002
crossref_primary_10_1093_oncolo_oyae291
crossref_primary_10_1007_s40265_018_0972_9
crossref_primary_10_1056_NEJMoa1903765
crossref_primary_10_1634_theoncologist_2019_0561
crossref_primary_10_1016_j_esmoop_2025_105105
crossref_primary_10_1371_journal_pone_0233571
crossref_primary_10_3389_fphar_2024_1345482
crossref_primary_10_1158_1078_0432_CCR_23_3465
crossref_primary_10_1007_s10549_022_06543_1
crossref_primary_10_3389_fonc_2018_00608
crossref_primary_10_1177_17588359251336623
crossref_primary_10_3390_cancers11091242
crossref_primary_10_1016_S1470_2045_19_30808_3
crossref_primary_10_1177_20420986241278498
crossref_primary_10_1016_j_breast_2023_103576
crossref_primary_10_1093_oncolo_oyaf123
crossref_primary_10_3389_fonc_2022_987012
crossref_primary_10_1038_s41416_020_01094_y
crossref_primary_10_1038_s41571_024_00935_6
crossref_primary_10_1097_MD_0000000000038828
crossref_primary_10_1186_s12967_025_06374_w
crossref_primary_10_3390_cancers13235994
crossref_primary_10_1097_OP9_0000000000000054
crossref_primary_10_2147_CMAR_S254365
crossref_primary_10_1016_j_vhri_2020_10_002
crossref_primary_10_1177_1078155220934531
crossref_primary_10_3389_fcell_2023_1148792
crossref_primary_10_1056_NEJMoa1810527
crossref_primary_10_1007_s11864_023_01109_9
crossref_primary_10_1016_j_breast_2022_10_005
crossref_primary_10_1007_s40801_022_00327_1
crossref_primary_10_1111_imj_14629
crossref_primary_10_1200_JCO_24_00144
crossref_primary_10_1002_cpdd_853
crossref_primary_10_1093_oncolo_oyac089
crossref_primary_10_1007_s40258_022_00731_2
crossref_primary_10_1055_a_2579_9530
crossref_primary_10_1016_j_clinsp_2024_100362
crossref_primary_10_1016_j_annonc_2023_08_011
crossref_primary_10_1186_s12885_018_4978_1
crossref_primary_10_1007_s40265_020_01461_2
crossref_primary_10_1001_jamanetworkopen_2024_61067
crossref_primary_10_3390_ijms23137079
crossref_primary_10_2217_fon_2019_0130
crossref_primary_10_1016_j_biocel_2024_106601
crossref_primary_10_1371_journal_pgen_1010563
crossref_primary_10_1186_s12885_023_11290_7
crossref_primary_10_1002_cncr_32931
crossref_primary_10_1007_s00520_024_08702_0
crossref_primary_10_1093_oncolo_oyae274
crossref_primary_10_1177_1758835918809610
crossref_primary_10_1007_s10549_020_05782_4
crossref_primary_10_1177_10781552231156521
crossref_primary_10_3389_fonc_2018_00308
crossref_primary_10_1080_14737167_2023_2263167
crossref_primary_10_1016_j_ctrv_2020_102086
crossref_primary_10_1055_a_2344_5269
crossref_primary_10_1017_erm_2021_3
crossref_primary_10_1007_s10549_020_05575_9
crossref_primary_10_1016_j_breast_2022_01_016
crossref_primary_10_3389_fonc_2024_1454844
crossref_primary_10_1093_oncolo_oyac075
crossref_primary_10_1186_s12919_021_00224_5
crossref_primary_10_3390_ijms24010865
crossref_primary_10_1002_jcph_2310
crossref_primary_10_1080_0284186X_2020_1853228
crossref_primary_10_1016_S1470_2045_24_00034_2
crossref_primary_10_1038_s41416_020_0967_7
crossref_primary_10_3390_ph13120418
crossref_primary_10_3390_cancers17172788
crossref_primary_10_1038_s41416_024_02589_8
crossref_primary_10_1007_s10549_023_06911_5
crossref_primary_10_3390_medsci9020042
crossref_primary_10_3390_cancers13205198
crossref_primary_10_1016_j_bcp_2022_115209
crossref_primary_10_1016_j_breast_2024_103729
crossref_primary_10_1158_1078_0432_CCR_20_2114
crossref_primary_10_1177_10781552221102884
crossref_primary_10_2217_imt_2020_0237
crossref_primary_10_1177_10781552221101799
crossref_primary_10_1177_17588359211000593
crossref_primary_10_1016_j_ejca_2024_114175
crossref_primary_10_1111_cas_14813
crossref_primary_10_17517_ksutfd_1341433
crossref_primary_10_3390_ijms242316607
crossref_primary_10_1016_j_annonc_2020_09_004
crossref_primary_10_3389_fonc_2025_1566146
crossref_primary_10_1007_s10549_020_05783_3
crossref_primary_10_1111_ajco_13840
crossref_primary_10_3389_fendo_2021_659537
crossref_primary_10_1080_14656566_2023_2258791
crossref_primary_10_1177_10781552211027931
crossref_primary_10_1177_10781552241301406
crossref_primary_10_1080_14740338_2025_2468357
crossref_primary_10_1007_s10549_023_07131_7
crossref_primary_10_2217_fon_2020_0573
crossref_primary_10_1053_j_seminoncol_2020_07_005
crossref_primary_10_1080_14656566_2019_1651293
crossref_primary_10_1016_j_esmorw_2025_100154
crossref_primary_10_1038_s41523_024_00625_7
crossref_primary_10_1093_ajhp_zxae168
crossref_primary_10_2147_DDDT_S380925
crossref_primary_10_1055_a_2018_9184
crossref_primary_10_1007_s12094_018_02010_w
crossref_primary_10_1001_jamanetworkopen_2024_61076
crossref_primary_10_1080_14740338_2021_1931116
crossref_primary_10_1097_CCO_0000000000000684
crossref_primary_10_1002_ijc_34562
crossref_primary_10_1016_j_mayocp_2024_08_014
crossref_primary_10_1186_s13046_023_02615_2
crossref_primary_10_1007_s10549_024_07469_6
crossref_primary_10_1016_j_clbc_2021_05_014
crossref_primary_10_1016_j_ejca_2021_12_030
crossref_primary_10_1016_j_breast_2024_103833
crossref_primary_10_1158_1078_0432_CCR_21_4179
crossref_primary_10_1016_j_breast_2024_103713
crossref_primary_10_1007_s11864_025_01310_y
crossref_primary_10_1016_S1470_2045_21_00472_1
crossref_primary_10_3390_biomedicines11020510
crossref_primary_10_3390_jcm13237441
crossref_primary_10_3390_cancers16244179
crossref_primary_10_21518_ms2025_253
crossref_primary_10_1007_s12094_023_03203_8
crossref_primary_10_1634_theoncologist_2018_0773
crossref_primary_10_2217_fon_2019_0169
crossref_primary_10_3390_cancers14112709
crossref_primary_10_3390_cells10020293
crossref_primary_10_3390_cancers16101838
crossref_primary_10_3892_mco_2024_2790
crossref_primary_10_1016_j_clbc_2021_12_008
crossref_primary_10_1016_j_ctarc_2020_100175
crossref_primary_10_1007_s00432_025_06246_2
crossref_primary_10_3390_cancers15061763
crossref_primary_10_1007_s00432_023_04588_3
crossref_primary_10_1007_s12029_020_00368_1
crossref_primary_10_1007_s12254_020_00588_y
crossref_primary_10_1016_j_clbc_2024_12_001
crossref_primary_10_1016_j_yexmp_2021_104652
crossref_primary_10_1200_JCO_19_00090
crossref_primary_10_1016_j_radonc_2022_10_023
crossref_primary_10_1200_EDBK_280845
crossref_primary_10_1007_s40273_023_01245_y
crossref_primary_10_1080_14737140_2021_1852934
crossref_primary_10_1007_s11864_024_01259_4
crossref_primary_10_1007_s12032_023_02255_8
crossref_primary_10_1080_14737140_2021_1960160
crossref_primary_10_1007_s13318_020_00635_3
crossref_primary_10_1080_14796694_2024_2377531
crossref_primary_10_1016_j_canrad_2022_11_003
crossref_primary_10_1177_17588359221083956
crossref_primary_10_1016_j_annonc_2020_09_010
crossref_primary_10_1016_j_esmoop_2024_104125
crossref_primary_10_2217_fon_2018_0942
crossref_primary_10_1038_s41523_025_00767_2
crossref_primary_10_2217_fon_2019_0044
crossref_primary_10_3390_cancers13061458
crossref_primary_10_4155_fmc_2018_0389
crossref_primary_10_1002_jso_25407
crossref_primary_10_1016_j_annder_2022_11_013
crossref_primary_10_1016_j_breast_2024_103815
crossref_primary_10_1038_s41523_022_00504_z
crossref_primary_10_1177_10781552231154009
crossref_primary_10_1016_j_breast_2019_01_009
crossref_primary_10_2174_0118715206319933241104100736
crossref_primary_10_1007_s10549_022_06574_8
crossref_primary_10_1002_onco_13833
crossref_primary_10_1186_s13058_020_01320_8
crossref_primary_10_1158_1078_0432_CCR_20_1068
crossref_primary_10_1161_HCG_0000000000000082
crossref_primary_10_1016_j_clbc_2022_08_011
crossref_primary_10_3390_molecules26154462
crossref_primary_10_1007_s11060_023_04276_9
crossref_primary_10_1007_s12282_023_01505_x
crossref_primary_10_1097_CCO_0000000000000984
crossref_primary_10_1016_j_annonc_2020_10_001
crossref_primary_10_1002_advs_202413103
crossref_primary_10_1136_jitc_2024_010430
crossref_primary_10_1080_14737140_2021_1996229
crossref_primary_10_1080_14737140_2019_1615889
crossref_primary_10_1016_j_currproblcancer_2021_100832
crossref_primary_10_1038_s44276_024_00107_0
crossref_primary_10_1111_tbj_13495
crossref_primary_10_3390_cancers15010316
crossref_primary_10_1177_1758835918815591
crossref_primary_10_3390_cancers14246100
crossref_primary_10_2340_1651_226X_2023_40365
crossref_primary_10_1158_1078_0432_CCR_20_4685
crossref_primary_10_3389_fonc_2023_1249160
crossref_primary_10_1007_s12254_024_01012_5
crossref_primary_10_1001_jama_2018_19323
crossref_primary_10_3390_cancers14204981
crossref_primary_10_1016_j_annonc_2021_05_353
crossref_primary_10_2217_bmt_2023_0020
crossref_primary_10_3390_cancers13174399
crossref_primary_10_1001_jamaoncol_2025_2092
crossref_primary_10_1016_j_micres_2025_128313
crossref_primary_10_1016_j_ejca_2024_115072
crossref_primary_10_1038_s41591_021_01562_9
crossref_primary_10_1080_13543784_2022_2097067
crossref_primary_10_1093_oncolo_oyac138
crossref_primary_10_3390_medicina60010168
crossref_primary_10_1080_03007995_2020_1783646
crossref_primary_10_1038_s41523_025_00722_1
crossref_primary_10_1186_s12885_025_14526_w
crossref_primary_10_1002_jcp_27832
crossref_primary_10_1186_s40360_024_00770_6
crossref_primary_10_3389_fonc_2025_1512496
crossref_primary_10_1016_j_clbc_2020_09_010
crossref_primary_10_1016_j_bulcan_2022_09_007
crossref_primary_10_1016_j_breast_2023_01_005
crossref_primary_10_1016_j_clbc_2024_01_002
crossref_primary_10_1177_10781552231174593
crossref_primary_10_1177_17588359211022881
crossref_primary_10_1186_s13045_020_00880_8
crossref_primary_10_3390_ijms241914427
crossref_primary_10_1007_s10549_018_4901_0
crossref_primary_10_1111_tbj_13637
crossref_primary_10_1177_1178223420944864
crossref_primary_10_1007_s40259_019_00337_6
crossref_primary_10_3389_fonc_2021_777867
crossref_primary_10_3390_ijms21082921
crossref_primary_10_1002_cncr_33620
crossref_primary_10_3390_genes12020285
crossref_primary_10_1007_s40262_022_01206_2
crossref_primary_10_1016_j_ejca_2021_03_042
crossref_primary_10_3389_fmolb_2021_707295
crossref_primary_10_1093_annonc_mdz439
crossref_primary_10_2147_OTT_S240655
crossref_primary_10_1007_s12282_021_01239_8
crossref_primary_10_2147_BCTT_S438366
crossref_primary_10_3389_fonc_2023_1203684
crossref_primary_10_1371_journal_pone_0253722
crossref_primary_10_12688_f1000research_142460_1
crossref_primary_10_1055_a_1811_6148
crossref_primary_10_1159_000504405
crossref_primary_10_1093_oncolo_oyad207
crossref_primary_10_1007_s12282_024_01571_9
crossref_primary_10_3390_cancers13215397
crossref_primary_10_3390_cancers16081490
crossref_primary_10_1016_j_breast_2021_05_008
crossref_primary_10_1016_j_clbc_2025_03_003
crossref_primary_10_1016_j_ijgc_2025_102028
crossref_primary_10_1111_tbj_13740
crossref_primary_10_1055_a_2286_6066
crossref_primary_10_3390_jcm14134568
crossref_primary_10_1016_j_coemr_2020_08_002
crossref_primary_10_1186_s12885_022_09624_y
crossref_primary_10_1007_s10549_023_07145_1
crossref_primary_10_1177_10781552241269677
crossref_primary_10_3390_cancers14133175
crossref_primary_10_1016_j_jgo_2023_101604
crossref_primary_10_1016_j_bulcan_2021_04_007
crossref_primary_10_1080_14737140_2025_2498994
crossref_primary_10_1016_j_ctro_2020_11_010
crossref_primary_10_3390_cancers15225463
crossref_primary_10_1016_j_jtha_2022_12_001
crossref_primary_10_1093_ajhp_zxz121
crossref_primary_10_1007_s40801_023_00391_1
crossref_primary_10_1038_s41571_023_00840_4
crossref_primary_10_1093_eurheartj_ehac244
crossref_primary_10_1186_s12885_021_08973_4
crossref_primary_10_2217_fon_2020_1264
crossref_primary_10_1177_1758835920943065
crossref_primary_10_2478_raon_2022_0020
crossref_primary_10_1016_j_ejmech_2025_117465
crossref_primary_10_1016_j_bulcan_2025_04_002
crossref_primary_10_1159_000502565
crossref_primary_10_1016_j_esmoop_2024_102995
crossref_primary_10_3390_cancers16203442
crossref_primary_10_1007_s12272_022_01402_5
crossref_primary_10_2147_CMAR_S250632
crossref_primary_10_1007_s00228_020_02895_z
crossref_primary_10_1016_j_drup_2024_101103
crossref_primary_10_1158_1078_0432_CCR_21_2600
crossref_primary_10_3389_fonc_2021_658054
crossref_primary_10_1007_s40264_023_01334_z
crossref_primary_10_1038_s41416_025_02951_4
crossref_primary_10_1016_j_annonc_2023_09_3104
crossref_primary_10_1080_14712598_2020_1752176
crossref_primary_10_1038_s41523_021_00222_y
crossref_primary_10_1038_s41591_025_03935_w
crossref_primary_10_1016_j_isci_2025_112620
crossref_primary_10_1038_s41598_025_97071_7
crossref_primary_10_1055_a_1880_0087
crossref_primary_10_3390_medicina59030557
crossref_primary_10_1007_s12672_025_02820_9
crossref_primary_10_1177_17588359211022890
crossref_primary_10_3390_cells8040321
crossref_primary_10_1007_s11912_019_0769_3
crossref_primary_10_1038_s41467_025_58647_z
crossref_primary_10_1080_03007995_2018_1503484
crossref_primary_10_1016_j_ctarc_2020_100201
crossref_primary_10_3390_cancers14133159
crossref_primary_10_1111_ajco_13555
crossref_primary_10_1158_1078_0432_CCR_23_0561
crossref_primary_10_3390_ijms232314534
crossref_primary_10_7759_cureus_71817
crossref_primary_10_1186_s40001_025_02806_x
crossref_primary_10_1016_j_clbc_2021_10_001
crossref_primary_10_1007_s11523_021_00838_x
crossref_primary_10_1186_s12885_020_6527_y
crossref_primary_10_1080_17425255_2019_1559816
crossref_primary_10_1186_s12943_023_01805_y
crossref_primary_10_1016_j_clbc_2021_10_007
crossref_primary_10_3390_ijms26073357
crossref_primary_10_1016_j_sagf_2025_06_007
crossref_primary_10_1158_1078_0432_CCR_19_3271
crossref_primary_10_1186_s12951_024_02309_7
crossref_primary_10_1093_oncolo_oyac205
crossref_primary_10_1080_21556660_2022_2107834
crossref_primary_10_1007_s10147_021_02013_8
crossref_primary_10_1080_14737140_2020_1834385
crossref_primary_10_1126_science_abc1495
crossref_primary_10_1186_s12916_023_03238_2
crossref_primary_10_3390_cancers14215388
crossref_primary_10_1007_s12254_018_0450_9
crossref_primary_10_1038_s41467_025_56096_2
crossref_primary_10_1038_s41523_022_00399_w
crossref_primary_10_1016_j_breast_2021_12_008
crossref_primary_10_1080_14740338_2021_1983541
crossref_primary_10_1007_s12094_020_02327_5
crossref_primary_10_1038_s41588_023_01507_7
crossref_primary_10_1016_j_breast_2022_09_006
crossref_primary_10_3390_ijms24054522
crossref_primary_10_1016_j_ejca_2021_11_010
crossref_primary_10_1186_s13058_024_01843_4
crossref_primary_10_1177_17588359231178125
crossref_primary_10_3390_biom13091422
crossref_primary_10_1002_advs_202409588
crossref_primary_10_1002_cam4_7249
crossref_primary_10_1177_17588359221113694
crossref_primary_10_1007_s00508_023_02254_9
crossref_primary_10_1186_s12916_023_03017_z
crossref_primary_10_3389_fonc_2021_651723
crossref_primary_10_1007_s12094_021_02688_5
crossref_primary_10_1038_s41571_018_0059_2
crossref_primary_10_1007_s12609_024_00563_0
crossref_primary_10_1016_j_breast_2025_104485
crossref_primary_10_1007_s00210_025_04204_w
crossref_primary_10_1177_15330338221090351
crossref_primary_10_1002_cncr_33650
crossref_primary_10_1073_pnas_2304619121
crossref_primary_10_1080_0284186X_2019_1684559
crossref_primary_10_1186_s13058_023_01701_9
crossref_primary_10_3390_cancers12123684
crossref_primary_10_1007_s10549_020_05755_7
crossref_primary_10_1007_s40262_020_00930_x
crossref_primary_10_1016_j_phrs_2020_105241
crossref_primary_10_2217_fon_2022_0552
crossref_primary_10_1080_14737140_2019_1674651
crossref_primary_10_1007_s10549_022_06823_w
crossref_primary_10_1038_s41598_021_83622_1
crossref_primary_10_1016_j_breast_2021_07_002
crossref_primary_10_1016_j_annonc_2020_12_013
crossref_primary_10_1007_s12325_020_01552_2
crossref_primary_10_1007_s11912_024_01540_7
crossref_primary_10_1016_j_annonc_2024_10_015
crossref_primary_10_1080_14740338_2023_2181338
crossref_primary_10_1177_10781552211007202
crossref_primary_10_1007_s11912_020_00917_8
crossref_primary_10_3390_ijerph20010512
crossref_primary_10_1038_s41598_024_67126_2
crossref_primary_10_1111_tbj_13532
crossref_primary_10_3390_jpm11050407
crossref_primary_10_1080_14740338_2025_2464113
crossref_primary_10_1158_1541_7786_MCR_20_0600
crossref_primary_10_18632_aging_206257
crossref_primary_10_1186_s12885_025_14194_w
crossref_primary_10_1002_prp2_599
crossref_primary_10_1007_s00228_024_03715_4
crossref_primary_10_1007_s11654_018_0105_7
crossref_primary_10_1245_s10434_025_17861_1
crossref_primary_10_1016_j_currproblcancer_2025_101235
crossref_primary_10_1038_s41416_021_01415_9
crossref_primary_10_3390_jcm12052044
crossref_primary_10_2147_CMAR_S284556
crossref_primary_10_1016_j_annonc_2020_12_003
crossref_primary_10_1186_s13046_020_01693_w
crossref_primary_10_3390_ph16101340
crossref_primary_10_3389_fmed_2021_658747
crossref_primary_10_18663_tjcl_1639022
crossref_primary_10_3389_fonc_2024_1378563
crossref_primary_10_3390_cancers15041303
crossref_primary_10_1177_10781552231163121
crossref_primary_10_3389_fphar_2023_1244597
crossref_primary_10_1038_s41417_024_00747_x
crossref_primary_10_1016_j_ctrv_2022_102496
crossref_primary_10_1016_j_ctrv_2023_102670
crossref_primary_10_1177_10781552241305417
ContentType Journal Article
DBID NPM
7X8
DOI 10.1200/JCO.2018.78.9909
DatabaseName PubMed
MEDLINE - Academic
DatabaseTitle PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1527-7755
ExternalDocumentID 29860922
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.55
0R~
18M
2WC
34G
39C
4.4
53G
5GY
5RE
8F7
AAQQT
AARDX
AAWTL
AAYEP
AAYOK
ABJNI
ABOCM
ACGFO
ACGFS
ACGUR
ADBBV
AEGXH
AENEX
AIAGR
ALMA_UNASSIGNED_HOLDINGS
AWKKM
BAWUL
BYPQX
C45
CS3
DIK
EBS
EJD
F5P
F9R
FBNNL
FD8
GX1
H13
HZ~
IH2
K-O
KQ8
L7B
LSO
MJL
N9A
NPM
O9-
OK1
OVD
OWW
P2P
QTD
R1G
RHI
RLZ
RUC
SJN
SV3
TEORI
TR2
TWZ
UDS
VVN
WH7
X7M
YCJ
YFH
YQY
7X8
ABBLC
ID FETCH-LOGICAL-c409t-be459173cdaa112b20121f01597974a57961f8bbeb4373c1165a10a5959db0862
IEDL.DBID 7X8
ISICitedReferencesCount 819
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000445668100002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1527-7755
IngestDate Fri Sep 05 06:40:06 EDT 2025
Thu Jan 02 23:03:27 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 24
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c409t-be459173cdaa112b20121f01597974a57961f8bbeb4373c1165a10a5959db0862
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
PMID 29860922
PQID 2049945190
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2049945190
pubmed_primary_29860922
PublicationCentury 2000
PublicationDate 2018-08-20
PublicationDateYYYYMMDD 2018-08-20
PublicationDate_xml – month: 08
  year: 2018
  text: 2018-08-20
  day: 20
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of clinical oncology
PublicationTitleAlternate J Clin Oncol
PublicationYear 2018
SSID ssj0014835
Score 2.7084312
Snippet Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 2465
Title Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
URI https://www.ncbi.nlm.nih.gov/pubmed/29860922
https://www.proquest.com/docview/2049945190
Volume 36
WOSCitedRecordID wos000445668100002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fa9swEBZrO0pf9iPdj3RbucHIU9Q6thXLexlZSNYMkpkshbwFyZK3QGdnsduS_U37I3enuMvbGPTFIIywzZ3O3-lO38fYOxHhahZC8FBYj4ddFXEdGsmVVqpjQxEoI53YRDSZyPk8TuoNt7Juq7yLiS5QmyKlPXJM0hGbExeK92H1k5NqFFVXawmNPXYQIJQhr47muypCKJ3AJim3IooUoi5TomOcf-5_ob4ueRbJMwzI_wCY7kczfHzfV3zCHtUQE3pbn3jKHti8wQ7HdRG9wVrJlq5604bZ7vRV2YYWJDsi680x-43D0sJoNIKpyk3xY_nLGqDOww0UGUyXGi2bYsINeBeG1GRNGyd5BcscLhAMF7kFxKV2hYk9T1x72I1tgyscwIC0afFpV_BpXdxW32HopH_-TgCfT-w3x0sOvbpTAT5SD30FfRqt38OYiHwHg689Hjxjl8PBrH_Ba3UHnmJOWXGNnoC5YpAa9IqOr31il8sQncQR5jiKzsh2Mqm11cS-lBJNkOp4SsQiNpoSsedsP8fveMlAW5WlCCRTT0dhmAUqjiODUEsa1ZU66zbZ2zuDLXD1UElE5ba4Lhc7kzXZi63VF6stzcfCj2XXi33_5D9mv2JH5E202ex7r9lBhrHDvmEP05tqWa5PnVvidZKM_wAdfOza
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phase+III+Randomized+Study+of+Ribociclib+and+Fulvestrant+in+Hormone+Receptor-Positive%2C+Human+Epidermal+Growth+Factor+Receptor+2-Negative+Advanced+Breast+Cancer%3A+MONALEESA-3&rft.jtitle=Journal+of+clinical+oncology&rft.au=Slamon%2C+Dennis+J&rft.au=Neven%2C+Patrick&rft.au=Chia%2C+Stephen&rft.au=Fasching%2C+Peter+A&rft.date=2018-08-20&rft.eissn=1527-7755&rft.volume=36&rft.issue=24&rft.spage=2465&rft_id=info:doi/10.1200%2FJCO.2018.78.9909&rft_id=info%3Apmid%2F29860922&rft_id=info%3Apmid%2F29860922&rft.externalDocID=29860922
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-7755&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-7755&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-7755&client=summon